{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T11:54:51Z","timestamp":1753876491303,"version":"3.41.2"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Pfizer grant and Georgetown Lombardi Cancer Center"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background and Introduction<\/jats:title>\n                  <jats:p>Over the last decade, treatment of patients with advanced non-small cell lung cancer (NSCLC) has become dependent on tissue and\/or blood biomarkers to guide treatment decisions. Timely access to comprehensive biomarker and tumor signature information is crucial for diagnostic testing. With the rapid development and implementation of complex biomarker testing, comprehensive molecular profiling with in-depth analysis of DNA, RNA, and proteins can be easily performed. Initial data from the MedStar Health system showed considerable disparities in the use of next generation sequencing (NGS) between hospitals, and there is a clear need to improve education and understanding regarding which cases are appropriate for NGS, as well as the use of protocols to make those decisions in an expeditious manner.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>Clinical pathways are systems-based tools that aim to create greater transparency around care decision making, therapeutic selection, and care delivery. They enhance quality and efficiency by reducing non-value-added intra-provider variability in care. We aimed to create a comprehensive clinical pathway system, the Targetable Molecular Algorithm (TMA), to increase the understanding and use of NGS in NSCLC by physicians in training, oncology nurse navigators, nurse practitioners, and general oncologists.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>We provide an overview of the implementation of the platform along with navigation guide. A realistic case study\u2014a typical clinical workflow for a patient requiring NGS testing with an EGFR mutation\u2014is also reviewed, demonstrating how the TMA platform can be applied. Additionally, we highlight the importance of the resource, and discuss its strengths, weaknesses, and potential future applications.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results and Conclusion<\/jats:title>\n                  <jats:p>This new and innovative pathway system will make decision-making easier for clinicians trying to understand the appropriate tests and treatment algorithms for their patients. Our aim is to increase the appropriate and timely use of NGS among health-system providers with the hope that this system will empower physicians to provide better care by providing a quick, simple, user-friendly tool for comprehensive patient care.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jamiaopen\/ooae124","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T20:10:26Z","timestamp":1730923826000},"source":"Crossref","is-referenced-by-count":0,"title":["Targetable molecular algorithm and training platform development for the treatment of non-small cell lung cancer"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4015-7056","authenticated-orcid":false,"given":"Krithika","family":"Bhuvaneshwar","sequence":"first","affiliation":[{"name":"Georgetown University Innovation Center for Biomedical Informatics (Georgetown-ICBI), Georgetown University Medical Center , Washington, DC 20007,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0191-8684","authenticated-orcid":false,"given":"Chul","family":"Kim","sequence":"additional","affiliation":[{"name":"Oncology, Medstar Georgetown Cancer Center , Washington, DC 20007,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaushal","family":"Parikh","sequence":"additional","affiliation":[{"name":"Oncology, Hackensack Meridian Health , Neptune City, NJ 07753,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua E","family":"Reuss","sequence":"additional","affiliation":[{"name":"Oncology, Medstar Georgetown Cancer Center , Washington, DC 20007,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camelia","family":"Bencheqroun","sequence":"additional","affiliation":[{"name":"Georgetown University Innovation Center for Biomedical Informatics (Georgetown-ICBI), Georgetown University Medical Center , Washington, DC 20007,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anvitha G","family":"Agraharam","sequence":"additional","affiliation":[{"name":"Georgetown University Innovation Center for Biomedical Informatics (Georgetown-ICBI), Georgetown University Medical Center , Washington, DC 20007,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayesha","family":"Munir","sequence":"additional","affiliation":[{"name":"Oncology, Medstar Georgetown Cancer Center , Washington, DC 20007,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adil","family":"Alaoui","sequence":"additional","affiliation":[{"name":"Georgetown University Innovation Center for Biomedical Informatics (Georgetown-ICBI), Georgetown University Medical Center , Washington, DC 20007,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuriy","family":"Gusev","sequence":"additional","affiliation":[{"name":"Georgetown University Innovation Center for Biomedical Informatics (Georgetown-ICBI), Georgetown University Medical Center , Washington, DC 20007,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina G","family":"Veytsman","sequence":"additional","affiliation":[{"name":"Oncology, Medstar Georgetown Cancer Center , Washington, DC 20007,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,11,6]]},"reference":[{"key":"2024110620101956500_ooae124-B1","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.2013.49.4799","article-title":"Precision oncology: an overview","volume":"31","author":"Garraway","year":"2013","journal-title":"JCO"},{"key":"2024110620101956500_ooae124-B2","doi-asserted-by":"crossref","first-page":"12316","DOI":"10.18632\/oncotarget.24384","article-title":"Precision oncology in advanced cancer patients improves overall survival with lower weekly healthcare costs","volume":"9","author":"Haslem","year":"2018","journal-title":"Oncotarget"},{"key":"2024110620101956500_ooae124-B3","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.cllc.2017.04.004","article-title":"Genomic profiling of advanced non-small cell lung cancer in community settings: gaps and opportunities","volume":"18","author":"Gutierrez","year":"2017","journal-title":"Clin Lung Cancer"},{"key":"2024110620101956500_ooae124-B4","first-page":"e60-7","article-title":"Molecular testing patterns in metastatic non-small cell lung cancer","volume":"22","author":"MacLean","year":"2016","journal-title":"Am J Manag Care"},{"key":"2024110620101956500_ooae124-B5","article-title":"Trends in the molecular diagnosis of lung cancer, results from an online market research survey","author":"Celine Audibert","year":"2017","journal-title":"Friends Cancer Res"},{"key":"2024110620101956500_ooae124-B6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00159","article-title":"ALK testing trends and patterns among community practices in the United States","volume":"2","author":"Illei","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"2024110620101956500_ooae124-B7","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.jtho.2020.05.002","article-title":"The International Association for the Study of Lung Cancer Global Survey on molecular testing in lung cancer","volume":"15","author":"Smeltzer","year":"2020","journal-title":"J Thorac Oncol"},{"key":"2024110620101956500_ooae124-B8","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.chest.2021.04.014","article-title":"Molecular biomarker and programmed death-ligand 1 expression testing in patients with advanced stage non-small cell lung cancer across North Carolina community hospitals","volume":"160","author":"Rivera","year":"2021","journal-title":"Chest"},{"key":"2024110620101956500_ooae124-B9","doi-asserted-by":"crossref","first-page":"e0156728","DOI":"10.1371\/journal.pone.0156728","article-title":"Real-world patterns of EGFR testing and treatment with erlotinib for non-small cell lung cancer in the United States","volume":"11","author":"Enewold","year":"2016","journal-title":"PLoS One"},{"key":"2024110620101956500_ooae124-B10","doi-asserted-by":"crossref","first-page":"e233","DOI":"10.1016\/j.cllc.2016.11.002","article-title":"Utilization patterns and trends in epidermal growth factor receptor (EGFR) mutation testing among patients with newly diagnosed metastatic lung cancer","volume":"18","author":"Shen","year":"2017","journal-title":"Clin Lung Cancer"},{"key":"2024110620101956500_ooae124-B11","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1136\/bmjebm-2019-111234","article-title":"Clinical pathways on a mobile device","volume":"25","author":"Barrett","year":"2020","journal-title":"BMJ EBM"},{"year":"2023","author":"Kluwer","key":"2024110620101956500_ooae124-B12"}],"container-title":["JAMIA Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jamiaopen\/article-pdf\/7\/4\/ooae124\/60454464\/ooae124.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jamiaopen\/article-pdf\/7\/4\/ooae124\/60454464\/ooae124.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T20:10:32Z","timestamp":1730923832000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jamiaopen\/article\/doi\/10.1093\/jamiaopen\/ooae124\/7879472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,8]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10,8]]}},"URL":"https:\/\/doi.org\/10.1093\/jamiaopen\/ooae124","relation":{},"ISSN":["2574-2531"],"issn-type":[{"type":"electronic","value":"2574-2531"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,10,8]]},"article-number":"ooae124"}}